Revolutionizing our understanding of Parkinson’s disease: Dr. Heinz Reichmann’s pioneering research and future research direction
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Millions of individuals around the world are afflicted with Parkinson's disease (PD), a prevalent and incapacitating neurodegenerative disorder. Dr. Reichmann, a distinguished professor and neurologist, has made substantial advancements in the domain of PD research, encompassing both fundamental scientific investigations and practical applications. His research has illuminated the etiology and treatment of PD, as well as the function of energy metabolism and premotor symptoms. As a precursor to a number of neurotransmitters and neuromodulators that are implicated in the pathophysiology of PD, he has also investigated the application of tryptophan (Trp) derivatives in the disease. His principal findings and insights are summarized and synthesized in this narrative review article, which also emphasizes the challenges and implications for future PD research. This narrative review aims to identify and analyze the key contributions of Reichmann to the field of PD research, with the ultimate goal of informing future research directions in the domain. By examining Reichmann's work, the study seeks to provide a comprehensive understanding of his major contributions and how they can be applied to advance the diagnosis and treatment of PD. This paper also explores the potential intersection of Reichmann's findings with emerging avenues, such as the investigation of Trp and its metabolites, particularly kynurenines, which could lead to new insights and potential therapeutic strategies for managing neurodegenerative disorders like PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglial Activation and Chronic Neurodegeneration
Lull, M. E., & Block, M. L. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.05.014 · Cited by 1,047
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598
Pathogenesis of Parkinson disease—the gut–brain axis and environmental factors
Klingelhoefer, L., & Reichmann, H. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.197 · Cited by 598
Environmental toxicity, oxidative stress and apoptosis: Ménage à Trois
Franco, R., Sánchez-Olea, R., Reyes-Reyes, E. M., & Panayiotidis, M. I. (2009) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2008.11.012 · Cited by 541
BDNF as a Promising Therapeutic Agent in Parkinson’s Disease
Palasz, E., Wysocka, A., Gasiorowska, A., Chalimoniuk, M., Niewiadomski, W., & Niewiadomska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031170 · Cited by 504
Mitochondrial dysfunction and mitophagy in parkinson’s disease: from mechanism to therapy
Malpartida, A. B., Williamson, M., Narendra, D. P., Wade-Martins, R., & Ryan, B. J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.11.007 · Cited by 482
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463
Pan-Montojo, F., Schwarz, M., Winkler, C., Arnhold, M., O'Sullivan, G. A., Pal, A., Said, J., Marsico, G., Verbavatz, J.-M., Rodrigo-Angulo, M., et al. (2012) · Scientific Reports · doi:10.1038/srep00898 · Cited by 405
How important is tryptophan in human health?
Kałużna-Czaplińska, J., Gątarek, P., Chirumbolo, S., Chartrand, M. S., & Bjørklund, G. (2019) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2017.1357534 · Cited by 333
The identity and function of microglia in neurodegeneration
Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308
Role of ketogenic diets in neurodegenerative diseases (Alzheimer's disease and Parkinson's disease)
Włodarek, D. (2019) · Nutrients · doi:10.3390/nu11010169 · Cited by 301
Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial
Phillips, M. C. L., Murtagh, D. K. J., Gilbertson, L. J., Asztely, F. J. S., & Lynch, C. D. P. (2018) · Movement Disorders · doi:10.1002/mds.27390 · Cited by 292
Biomarkers for Parkinson’s Disease: Recent Advancement
Lotankar, S., Prabhavalkar, K. S., & Bhatt, L. K. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0183-5 · Cited by 282
Mithaiwala, M. N., Santana-Coelho, D., Porter, G. A., & O’Connor, J. C. (2021) · Cells · doi:10.3390/cells10061548 · Cited by 190
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
Valotto Neto, L. J., Reverete de Araujo, M., Moretti Junior, R. C., Mendes Machado, N., Joshi, R. K., dos Santos Buglio, D., Barbalho Lamas, C., Direito, R., Fornari Laurindo, L., Tanaka, M., et al. (2024) · Antioxidants · doi:10.3390/antiox13040393 · Cited by 146
Self-citationClinical Criteria for the Diagnosis of Parkinson’s Disease
Reichmann, H. (2010) · Neurodegenerative Diseases · doi:10.1159/000314478 · Cited by 145
Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Tryptophan metabolism: Mechanism-oriented therapy for neurological and psychiatric disorders
Li, D., Yu, S., Long, Y., Shi, A., Deng, J., Ma, Y., Wen, J., Li, X., Liu, S., Zhang, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985378 · Cited by 129
Kwok, J. Y. Y., Choi, K. C., & Chan, H. Y. L. (2016) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2016.09.016 · Cited by 115
Mogi, M., Harada, M., Kiuchi, K., Kojima, K., Kondo, T., Narabayashi, H., Rausch, D., Riederer, P., Jellinger, K., & Nagatsu, T. (1988) · Journal of Neural Transmission · doi:10.1007/bf01244634 · Cited by 101
Disorders of Gastrointestinal Motility in Neurologie Diseases
CAMILLERI, M. (1990) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62574-9 · Cited by 91
Visceral Inflammation and Immune Activation Stress the Brain
Holzer, P., Farzi, A., Hassan, A. M., Zenz, G., Jačan, A., & Reichmann, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01613 · Cited by 84
Research on the Premotor Symptoms of Parkinson’s Disease: Clinical and Etiological Implications
Chen, H., Burton, E. A., Ross, G. W., Huang, X., Savica, R., Abbott, R. D., Ascherio, A., Caviness, J. N., Gao, X., Gray, K. A., et al. (2013) · Environmental Health Perspectives · doi:10.1289/ehp.1306967 · Cited by 83
The physiological correlates of interpersonal space
Candini, M., Battaglia, S., Benassi, M., di Pellegrino, G., & Frassinetti, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-82223-2 · Cited by 73
Perspectives on recent advances in the understanding and treatment of Parkinson's disease
Schapira, A. H., Agid, Y., Barone, P., Jenner, P., Lemke, M. R., Poewe, W., Rascol, O., Reichmann, H., & Tolosa, E. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02793.x · Cited by 69
Minniti, G., Laurindo, L. F., Machado, N. M., Duarte, L. G., Guiguer, E. L., Araujo, A. C., Dias, J. A., Lamas, C. B., Nunes, Y. C., Bechara, M. D., et al. (2023) · Life · doi:10.3390/life13122270 · Cited by 56
Oxidative Stress to Dopaminergic Neurons as Models of Parkinson's Disease
GILLE, G., HUNG, S., REICHMANN, H., & RAUSCH, W. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1296.066 · Cited by 53
Poles, M. Z., Nászai, A., Gulácsi, L., Czakó, B. L., Gál, K. G., Glenz, R. J., Dookhun, D., Rutai, A., Tallósy, S. P., Szabó, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.717157 · Cited by 49
Self-citationMitochondrial pyruvate carrier function in health and disease across the lifespan
Buchanan, J., & Taylor, E. (2020) · Biomolecules · doi:10.3390/biom10081162 · Cited by 40
Cited by
Parkinson’s Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation
Tanaka, M. (2025) · doi:10.20944/preprints202506.2099.v2 · Cited by 57
Self-citationTanaka, M. (2025) · doi:10.20944/preprints202412.0679.v2 · Cited by 42
Self-citationQuinoline Quest: Kynurenic Acid Strategies for Next-Generation Therapeutics via Rational Drug Design
Tanaka, M., Szatmári, I., & Vécsei, L. (2025) · doi:10.20944/preprints202503.2399.v1 · Cited by 30
Self-citationTanaka, M. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/197425 · Cited by 27
Self-citationTanaka, M., Battaglia, S., & Liloia, D. (2025) · Biomedicines · doi:10.3390/biomedicines13051045 · Cited by 24
“These innovative findings herald an era of renewed hope for deciphering and ultimately conquering Parkinson’s disease [77].”
Self-citation
Metadata
- Authors
- Tanaka, M., & Vécsei, L.
- Venue
- Journal of Neural Transmission
- Published
- 2024-08-07
- Volume
- 131
- Issue
- 12
- Pages
- 1367-1387
- ISSN
- 0300-9564 (ISSN-L)
- 1435-1463
- OpenAlex
- W4401396748
- Cited by
- 22
- References
- 32
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.